Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study.
Autor: | Al Sulaiman K; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia. alsulaimankh@hotmail.com.; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. alsulaimankh@hotmail.com.; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. alsulaimankh@hotmail.com.; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia. alsulaimankh@hotmail.com.; Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia. alsulaimankh@hotmail.com., Korayem GB; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia., Altebainawi AF; Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Hail, Saudi Arabia., Al Harbi S; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia., Alissa A; Pharmaceutical Care Services, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia., Alharthi A; Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia., Kensara R; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia., Alfahed A; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia., Vishwakarma R; Statistics Department, European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Al Haji H; Respiratory Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Almohaimid N; Respiratory Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Al Zumai O; Respiratory Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Alrubayan F; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Asiri A; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Alkahtani N; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Alolayan A; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Alsohimi S; Pharmaceutical Services Department, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.; Phamacy Department, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia., Melibari N; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Almagthali A; Pharmaceutical Services Department, King Abdulaziz University Hospital, Jeddah, Saudi Arabia., Aljahdali S; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Alenazi AA; Pharmaceutical Care Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia., Alsaeedi AS; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Al Ghamdi G; King Abdullah International Medical Research Center, King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Al Faris O; Respiratory Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Alqahtani J; Respiratory Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia., Al Qahtani J; Respiratory Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Alshammari KA; Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Hail, Saudi Arabia., Alshammari KI; Department of Internal Medicine, Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia., Aljuhani O; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. |
---|---|
Jazyk: | angličtina |
Zdroj: | Critical care (London, England) [Crit Care] 2022 Oct 03; Vol. 26 (1), pp. 304. Date of Electronic Publication: 2022 Oct 03. |
DOI: | 10.1186/s13054-022-04158-y |
Abstrakt: | Background: Inhaled nitric oxide (iNO) is used as rescue therapy in patients with refractory hypoxemia due to severe COVID-19 acute respiratory distress syndrome (ARDS) despite the recommendation against the use of this treatment. To date, the effect of iNO on the clinical outcomes of critically ill COVID-19 patients with moderate-to-severe ARDS remains arguable. Therefore, this study aimed to evaluate the use of iNO in critically ill COVID-19 patients with moderate-to-severe ARDS. Methods: This multicenter, retrospective cohort study included critically ill adult patients with confirmed COVID-19 treated from March 01, 2020, until July 31, 2021. Eligible patients with moderate-to-severe ARDS were subsequently categorized into two groups based on inhaled nitric oxide (iNO) use throughout their ICU stay. The primary endpoint was the improvement in oxygenation parameters 24 h after iNO use. Other outcomes were considered secondary. Propensity score matching (1:2) was used based on the predefined criteria. Results: A total of 1598 patients were screened, and 815 were included based on the eligibility criteria. Among them, 210 patients were matched based on predefined criteria. Oxygenation parameters (PaO Conclusion: In critically ill COVID-19 patients with moderate-to-severe ARDS, iNO rescue therapy is associated with improved oxygenation parameters but no mortality benefits. Moreover, iNO use is associated with higher odds of AKI, pneumonia, longer LOS, and fewer VFDs. (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |